Supriya Gupta, MD

🧬 New data from #Tandem2026: Dr. Fnu Amisha @amishagupta2012 of Moffitt Cancer Center presents findings showing that baseline and peri-infusion cytokine patterns correlate with immune-mediated toxicities after CD19 CAR-T in adult B-ALL. A step toward better predicting and managing CAR-T complications. 🎥 Watch on #VuMedi: tinyurl.com/4nvy3haw #CART #ALL #HemOnc #MedEd #VuMedi

Post-BCMA CAR-T cytopenias are common, prolonged, and clinically impactful. We analyzed the practical, real-world strategies to monitor and manage hematologic toxicities after #CART for #MM at Mayo Clinic @YiLinMDPhD @SupriyaGuptaMD @VincentRK @Taxkourel nature.com/articles/s4140…

Hotpot or BBQ? No need to choose. The future movers and shakers in #CellTherapy will have it all! #Tandem26 @ASTCT @MayoCancerCare #lymsm #mmsm @MayoHemeOnc @jdesr @SupriyaGuptaMD @MalvikaGuptaMD

Important and much needed step forward in R/R PCNSL #CART #lymsm

At #Tandem26 tomorrow, Amisha Fnu, MD (@amishagupta201), presents findings showing the refined elderly comorbidity index predicts post-transplant survival in older adults with AML and MDS. #MoffittTandem26 Learn more: bit.ly/4qEyGYr

With growing #CellTherapy volumes, how can we use large language models #LLM to automate #CART toxicity data abstraction & analysis? @MalvikaGuptaMD shares @MayoCancerCare experiences 🤖📊 @CIBMTR @ASTCT tandem.virtual-meeting.org/programme/pres… #AIinHealthcare #QualityImprovement

🧪 Dr. @SupriyaGuptaMD of Univ. of Minnesota presents ASH 2025 data: azer-cel + low-dose IL-2 shows 81% ORR, deep MRD-negative remissions & robust CAR-T persistence in post-auto CAR-T R/R LBCL. Watch on #VuMedi: tinyurl.com/4fxdzmex ASH 2025 Hub ➤ tinyurl.com/5c3k7ydn #ASH25 #DLBCLsm #HemOnc #MedEd

Impressive presentation by @SupriyaGuptaMD at #ASH25 - the world's largest hematology conference - on azer-cel safety & efficacy in LBCL post-CAR-T relapse setting . ✅ 81% response rate in CAR-T relapsed DLBCL ✅ 83% response rate in CAR-T naïve patients ✅ Off-the-shelf allogeneic therapy $IMU advancing important clinical research. #Biotech #CARTTherapy

Data presented at #ASH25 highlight new CAR T-cell approaches for relapsed/refractory B-cell lymphoma, including dual-target therapies, off-the-shelf CAR T, and options after prior CAR T relapse. Early studies suggest meaningful responses with manageable side effects. buff.ly/tEPH0Nj #HealthTree

ICYMI: See our article in today’s ASH News Daily highlighting Dr. Nancy Speck’s E Donnall Thomas Lecture and Prize on her groundbreaking research in CBF leukemia @ASH_hematology @JoselleCookMD #ASH25 @SupriyaGuptaMD ashpublications.org/ashnewsdaily/n…

#ASHkudos to Dr. Sanni, one of our fellows at #UMN who presented his research on HgSC disease cardiopulmonary risks and outcomes in inpatient setting. #ASH25

Excited to share our abstract on cardiotoxicities with CAR-T therapy at #ASH25 Stop by poster #6301 to say hi 👋 @ChrisGrahamMD @SupriyaGuptaMD

It’s been great working with the ASH News Daily #DreamTeam #ASH25 under the incredible leadership of @JoselleCookMD and @CKBrierley @ASH_hematology 🩸

Live from #ASH25: Amisha Fnu MD (@amishagupta2012) discusses the clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies. #MoffittASH25 @ASH_hematology

Join Fnu Amisha, MD at #ASH25 as she shares new insights for relapsed/refractory diffuse large B-cell lymphoma, acute myeloid leukemia and myelodysplastic syndrome. #MoffittASH25 @ASH_hematology #MDSsm #AML #Lymsm

The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ASH_hematology

Exciting session in Cell Therapy for #mmsm and #lysm ongoing in hall d2 moderated by @GKaurMD and Dr Bachy ! Some amazing dual targeted cart shows the future of we’re CART work is going including more tries for allo CAR’s #ASH2025

ICYMI: My piece covering Prof. Chiara Bonini’s inspiring Ham-Wasserman lecture was featured in today’s #ASHNewsDaily Prof. Bonini took us through a journey in gene editing, innovation and the rapidly evolving future of cancer immunotherapy. 🧬 Grab your copy today! #ASH25

UMN ladies of Lymphoma @UMNews @UMNHOT

Women of the University of Minnesota Hematologic Malignancies @UMNews @UMNHOT